Eli Lilly has announced its acquisition of SiteOne Therapeutics to enhance its pain management portfolio, focusing on the development of non-opioid treatments for chronic pain.

Information on the Target

SiteOne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative small molecule inhibitors targeting sodium channels to treat pain and other disorders characterized by neuronal hyperexcitability. Their lead candidate, STC-004, is a Phase 2 ready Nav1.8 inhibitor, which represents a potential next-generation non-opioid treatment specifically designed for patients suffering from chronic pain. SiteOne has dedicated over a decade to creating safer and more effective therapies with a reduced risk of addiction compared to conventional opioid medications.

In addition to STC-004, SiteOne is advancing several other drug candidates that exhibit selective activity towards specific ion channel subtypes. This research aims to expand treatment options for various conditions, including chronic cough and ocular surface pain. The company’s mission aligns with a growing demand for innovative pain management solutions that do not carry the adverse effects typically associated with opioid use.

Industry Overview in the United States

The pain management market in the United States is experiencing significant growth due to the alarming increase in the number of individuals affected by chronic pain conditions. This rise is attributed to factors such as the aging populatio